EDAP’s Focal One Robotic HIFU Platform to be Featured at 41st World Congress of Endourology and Uro-Technology Meeting (WCET 2024)
August 06, 2024 07:00 ET
|
EDAP TMS S.A.
Semi-Live Focal One Procedure to be Conducted on August 15th at 5:00 pm (KST) LYON, France, August 6, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies,...
EDAP Announces Interim Results from Phase 3 Study Evaluating Robotic HIFU for the Treatment of Deep Infiltrating Endometriosis
July 19, 2024 16:15 ET
|
EDAP TMS S.A.
Robotic HIFU therapy continues to maintain an excellent safety profile, confirming positive safety data from prior Phase 1 and 2 studies in patients with deep infiltrating endometriosisAt...
EDAP Appoints Fran Schulz to Board of Directors
July 08, 2024 07:00 ET
|
EDAP TMS S.A.
PDF Version LYON, France, July 8, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Fran Schulz to...
EDAP Appoints New Executive Leaders to Strengthen Europe and Middle East Commercial Operations
June 03, 2024 08:00 ET
|
EDAP TMS S.A.
New appointments bring significant commercial experience with a focus on growing key strategic markets Expands executive leadership in growing disruptive, robotics-based capital equipment in both...
EDAP to Present at the Jefferies Global Healthcare Conference
May 22, 2024 08:00 ET
|
EDAP TMS S.A.
LYON, France, May 22, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled...
EDAP Reports First Quarter 2024 Financial Results
May 16, 2024 08:00 ET
|
EDAP TMS S.A.
Strong Q1 2024 U.S. Focal One® HIFU procedure growth of +92% year-over-year Q1 2024 HIFU revenue of EUR 5.8 million ($6.3 million USD), an increase of 10.2% over Q1 2023Q1 2024 total revenue...
EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting
May 06, 2024 08:00 ET
|
EDAP TMS S.A.
Final results demonstrate a significantly higher salvage treatment free survival rate (STFS) at 30 months of 89.6% in the HIFU-treated arm versus 86.2% in patients who...
EDAP to Announce First Quarter 2024 Financial Results on May 16, 2024
May 02, 2024 08:00 ET
|
EDAP TMS S.A.
Company to host conference call and webcast on Thursday, May 16th at 8:30am EDT LYON, France, May 2, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based...
EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting
April 23, 2024 08:00 ET
|
EDAP TMS S.A.
LYON, France, April 23, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that final results from the HIFI Study, the largest clinical trial ever...
EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results
March 27, 2024 07:00 ET
|
EDAP TMS S.A.
Record Q4 2023 total revenue of EUR 19.6 million ($21.3 million USD) increased 24.8% over Q4 2022Record Q4 2023 HIFU revenue of EUR 7.5 million ($8.1 million USD), an increase of 38.8% over Q4...